- Home
- GNL vs KNSA Comparison
GNL vs KNSA Comparison
Compare GNL & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNL | KNSA |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GNL | KNSA |
|---|---|---|
| Price | $8.29 | $41.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $9.00 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 1.3M | 331.2K |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | ★ 9.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | ★ $751,333,000.00 | $597,973,000.00 |
| Revenue This Year | N/A | $62.63 |
| Revenue Next Year | N/A | $29.93 |
| P/E Ratio | ★ N/A | $87.85 |
| Revenue Growth | 17.63 | ★ 55.68 |
| 52 Week Low | $6.51 | $17.82 |
| 52 Week High | $8.40 | $42.98 |
Technical Indicators
Market Signals| Indicator | GNL | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 55.91 |
| Support Level | $8.20 | $40.05 |
| Resistance Level | $8.40 | $42.32 |
| Average True Range (ATR) | 0.13 | 1.51 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 82.47 | 56.97 |
Price Performance
Historical ComparisonAbout GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.